Cancer Etiology and Cancer Biomarkers

David Ann, Ph.D. 
David Ann, professor of the Department of Diabetes Complications & Metabolism, received his Ph.D. from Purdue University. His laboratory is investigating cancer metabolism to identify novel nutrient-restriction cancer therapy. A major focus of his team is to dissect the molecular mechanism by which tumor cells become auxotrophic for arginine.
 
Leslie Bernstein, Ph.D. 
Leslie Bernstein, professor and director of the Division of Biomarkers of Early Detection and Prevention, Department of Population Sciences, received her Ph.D. from UCLA.  Her research utilizes data from the California Teachers Study to examine questions of cancer etiology, prevention and the impact of modifiable risk factors.
 
Yuan Chen, Ph.D. 
Yuan Chen, professor of the Department of Molecular Medicine, received her Ph.D. from Rutgers University. Her laboratory is currently focusing on using chemical, biochemical and cellular approaches to study how changes in ubiquitin-like modifications influence major oncogenic pathways, such as c-Myc and Kras, in cancer pathogenesis.    
 
Warren Chow, M.D. 
Warren Chow, clinical professor in the Department of Medical Oncology & Therapeutics Research, received his M.D. from University of Health Sciences/the Chicago Medical School. He is interested in developing new therapeutics for treatment of sarcomas, which are less toxic and more efficacious.
 
Thanh Dellinger, M.D. 
Thanh Dellinger, assistant professor in the Department of Surgery, received her M.D. from University of California Irvine School of Medicine. Her research focuses on understanding the molecular pathways leading to ovarian and uterine cancers and the development of therapies to interdict these processes.
 
Robert Hickey, Ph.D.  
Robert Hickey, associate professor of the Department of Molecular Medicine, received his Ph.D. from City University of New York. He is interested in using mass spectrometry to identify novel cancer related biomarkers and their corresponding mechanistic role in the development and progression of the cancer.
 
Jeremy Jones, Ph.D. 
Jeremy Jones, associate research professor of the Department of Medical Oncology & Therapeutics Research, received his Ph.D. from Stanford University School of Medicine. His lab is pursuing a variety of approaches, including new androgen receptor inhibitor development, to attenuate the impact of prostate, kidney and bladder cancers. 
 
Michael Kahn, Ph.D. 
Michael Kahn, professor and chair of the Department of Molecular Medicine, received his Ph.D. from Yale University. His research team focuses on dissecting the signaling pathways in somatic and cancer stem cell development. Their second generation of CBP/-catenin antagonist is currently in the clinical trials for various cancers and liver fibrosis. 
 
Mark LaBarge, Ph.D. 
Mark LaBarge, professor of the Department of Population Sciences, received his Ph.D. from Stanford University. His team specializes in developing human cell systems to dissect the micro-environmental and tissue-level changes in breast that arise with age for understanding why aging is a major risk factor for breast cancer. 
 
Yilun Liu, Ph.D. 
Yilun Liu, professor and associate chair of the Department of Cancer Genetics and Epigenetics, received her Ph.D. from Yale University. Her team focuses on uncovering the molecular etiologies of developmental abnormalities, premature aging syndromes, malignancies and chemo-resistance by the clinical mutations of the RECQ DNA helicases. 
 
Linda Malkas, Ph.D. 
Dr. Malkas, the M.T. & B.A. Ahmadinia Professor in Molecular Oncology, received her Ph.D. from City University of New York. Her laboratory is focusing on developing compounds that target the novel cancer-associated protein proliferation cell nuclear antigen (PCNA) to disrupt DNA replication and the ability for cancer cell growth. 
 
Ravi Salgia, M.D., Ph.D. 
Ravi Salgia, the Arthur & Rosalie Kaplan Chair in Medical Oncology, Received his M.D. and Ph.D. from Loyola University School of Medicine. He is focused on identifying novel biomarkers for nonsmall cell lung cancer and developing targeted therapies related to lung cancer.
 
Victoria Seewaldt, M.D. 
Dr. Seewaldt, the Ruth Ziegler Chair in Population Sciences, received her M.D. from University of California Davis. Her research focuses on identifying signaling networks that promote breast cancer initiation with the goal of integrating novel functional imaging strategies with risk-marker to provide early detection of interval cancers. 
 
Binghui Shen, Ph.D. 
Binghui Shen, professor and chair of the Department of Cancer Genetics and Epigenetics, received his Ph.D. from Kansas State University. His team focuses on understanding the molecular functions of nucleases in DNA replication and repair, as well as identifying histone modifiers and their contribution to cancer. 
 
Yanhong Shi, Ph.D. 
Yanhong Shi, professor and director of the Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, received her Ph.D. from Northwestern University. Her laboratory focuses on characterizing the role of the nuclear receptor TLX signaling in neural stem cell self-renewal and differentiation for developing new treatment against neurological disorders.  
 
Christopher Sistrunk, Ph.D. 
Christopher Sistrunk, assistant professor of the Department of Population Sciences, received his Ph.D. from North Carolina State University. His team utilizes molecular pathology techniques to elicit specific biochemical profiles that can identify tumorigenesis at early time point than our current standard of care diagnosis tools. 
 
Jeremy Stark, Ph.D. 
Jeremy Stark, professor of the Department of Cancer Genetics and Epigenetics, received his Ph.D. from University of Washington. His team seeks to define the factors that limit chromosomal rearrangements during DNA double-stranded break repair to maintain genome stability, and to develop therapeutic targets for tumor radiosensitization.    
 
Zijie (ZJ) Sun, MD, Ph.D. 
Zijie Sun, M.D., Ph.D., is a professor at the Department of Cancer Biology. His research interest is focused on transcriptional control and cell signaling in development and tumorigenesis, especially using a variety of “cutting-edge” experimental approaches to uncover genomic and epigenetic alternations during the course of these biologic events.    
 
John Termini, Ph.D. 
John Termini, professor of the Department of Molecular Medicine and associate director of shared resources, received his Ph.D. from Columbia University. His team utilizes synthetic DNA chemistry and analytical methodologies to define how specific DNA base damage accumulates under physiological conditions to promote mutagenesis and cancer.
 
Edward Wenge Wang, M.D., Ph.D. 
Edward Wang, medical oncologist and assistant professor of the Department of Medical Oncology & Therapeutics Research, received his M.D. and Ph.D. from Harbin Medical University. He leads a laboratory at the Biomedical Research Center, focusing on development of new death receptor agonists and rescue of p53 from negative regulators for cancer treatment.
 
Qiong (Annabel) Wang Ph.D. 
Qiong Wang, assistant professor of the Department of Molecular & Cellular Endocrinology. Her team focuses on defining the mechanisms of adipose tissue remodeling in mammary glands to prevent metabolic disorders and breast cancer, as well as brown adipocyte heterogeneity in remodeling the energy-burning capacity in brown adipocytes. 
 
Xiaochun Yu, M.D., Ph.D. 
Xiaochun Yu, professor of the Department of Cancer Genetics and Epigenetics, received his Ph.D. from Kurume University. His team uses multidisciplinary approaches to identify novel signal transduction pathways mediated by post-translational modifications in DNA damage response and repair to preserve genome integrity.